Introduction
The current standard of care for patients with newly diagnosed glioblastoma includes maximal resection as feasible followed by radiotherapy (RT) and concomitant temozolomide (TMZ) chemotherapy and six cycles of maintenance TMZ chemotherapy (TMZ/RT ! TMZ) [1] . In recurrent glioblastoma, standards of care are less well defined. Alkylating chemotherapy, as a rechallenge with either temozolomide or nitrosoureas, or bevacizumab (Avastin V R , Roche, Reinach, Switzerland), a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), are currently used [2] . Bevacizumab received approval for the treatment of recurrent glioblastoma in the USA and many other countries including Switzerland, but not the European Union, in 2009, based on two phase II trials demonstrating radiographic response rates around 30% and 6-month progressionfree survival (PFS-6) rates of 43% and 29%, respectively [3, 4] . However, a subsequent phase III trial, EORTC 26101, did not show increased survival when bevacizumab was combined with lomustin compared with lomustin alone [5] . Yet, it remains unclear to what extent cross-over may have blunted an overall survival (OS) benefit in EORTC 26101; moreover, it is conceivable that the patients deriving most benefit from bevacizumab may not be typically included in clinical trials. Accordingly, this retrospective study used registry data of the Canton of Zurich to explore changes in outcome of glioblastoma with the introduction of bevacizumab on a population level.
Methods

Patient identification
All patients 18 years or older who were inhabitants of the Canton of Zurich and diagnosed with glioblastoma from 2010 to 2014 were included. Patient identification data were provided by the Cancer Registry of the Cantons of Zurich and Zug. The main basis for the acquisition of patients was pathology reports from private and public pathology institutions in the Canton of Zurich together with data on Zurich inhabitants diagnosed with glioblastoma from cancer registries of other cantons in Switzerland.
Disease characteristics
All tumors were classified according to the World Health Organization 2007 criteria in the local pathology departments [6] ; 286 of 310 diagnoses were made at the Institute of Neuropathology in Zurich. O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status determined by methylation-specific PCR was available in 148 patients. Isocitrate dehydrogenase (IDH) mutation status was obtained by immunohistochemistry for IDH1 R132H in 48 and by IDH1/2 sequencing in 206 patients, for a total of 254 patients with known IDH1/2 mutation status (%). Extent of resection was determined by postoperative magnetic resonance imaging (MRI) or, if MRI was not available, by cranial computed tomography (CT). Gross total resection was defined by the postoperative absence of contrast enhancement. Data on extent of resection determined by imaging were available in 286 (92.3%) patients but was not centrally reviewed.
Statistical analysis
PFS, PFS from first salvage therapy (PFS-2), post-recurrence survival (PRS) and OS curves were derived using the Kaplan-Meier method and compared by the log-rank test. PFS or OS were measured from the date of surgery to the date of progression or death. PFS-2 or PRS were measured from the date of first recurrence determined by imaging assessment to the date of progression or death, whichever came first. Patients without confirmed progression or death were censored for PFS, PFS-2, PRS or OS at last follow-up. Chi-square tests were carried out for analysis of nominal variables, the Mann-Whitney U test was used for quantitative variables. Cox proportional hazards regression models were used for univariate and multivariate analyses to test the association of clinical and molecular factors with outcome. The multivariate model was applied to all patients who had complete information on all tested co-variables [age, extent of resection, Karnofsky performance status (KPS) at time of diagnosis (before surgery), MGMT promoter methylation status, postsurgical therapy, bevacizumab treatment]. All statistical tests were two-tailed and a P value of 0.05 was set as statistically significant. All statistical analyses were carried out using IBM Statistics, Version 23 (SPSS IBM Corp., Armonk, NY, USA).
Ethics
This study was approved by the Ethics Committee of the Canton of Zurich (KEK-ZH-Nr. 2015-0437).
Results
Patient characteristics
A total of 310 glioblastoma patients diagnosed 2010-2014 in the Canton of Zurich were identified. The incidence rate, adjusted for the standard population in the Canton of Zurich (www.bfs. admin.ch), was 4.4 per 100 000 inhabitants per year in 2010-2014 compared with 3.9 per 100 000 persons per year in 2005-2009 [7] . Clinically secondary glioblastomas were not included in the present study. Patient characteristics at time of diagnosis are summarized in supplementary Table S1 , available at Annals of Oncology online. Compared with 2005-2009, the median age at time of diagnosis in the 2010-2014 cohort for patients with IDH wt tumors was higher with 64 years (P ¼ 0.022), whereas gender (P ¼ 0.516), KPS (P ¼ 0.182), and MGMT promoter methylation status (P ¼ 0.564) were similar. In the present cohort, more patients received a biopsy or an incomplete resection (P < 0.001). 
Outcome data
Outcome data by patient and tumor characteristics are summarized in Table 1 and in supplementary Table S3 Figure S1 , available at Annals of Oncology online) and 23.7 months versus 60.5 months (P ¼ 0.935) for patients with IDH mutant tumors ( Table 1) . Age (P < 0.001), KPS (P < 0.001), extent of resection (P < 0.001), MGMT promoter methylation status (P ¼ 0.007) and first-line treatment regimen (P < 0.001), but not age ( 
Univariate and multivariate analysis of risk of death
Univariate analysis of risk of death for all IDH wt patients 2010-2014 cohort revealed a prognostic role for younger age (P < 0.001), KPS (<70% P < 0.001; 90%-100% P ¼ 0.016; reference 70%-80%), extent of resection (incomplete resection P < 0.001; gross total resection P < 0.001; reference biopsy), MGMT promoter methylation status (P ¼ 0.008), postsurgical therapy (RT plus TMZ P < 0.001; RT alone P < 0.001; CT alone P < 0.001; reference no therapy), and bevacizumab treatment at any time during the course of disease (P < 0.001; note that the latter includes patients who did not receive any treatment beyond surgery at all) (supplementary Table S4 , available at Annals of Oncology online). Multivariate analysis identified age (P ¼ 0.001), KPS (<70% P ¼ 0.001; 90%-100% P ¼ 0.063; reference 70%-80%), extent of resection (incomplete resection P ¼ 0.003; gross total resection P < 0.001; reference biopsy), MGMT promoter methylation status (P < 0.001), and postsurgical therapy (RT plus TMZ P ¼ 0.009; RT alone P ¼ 0.061; CT alone P ¼ 0.494; reference no therapy) to be independently associated with OS; in contrast, bevacizumab treatment at any time during the disease course was not significant (P ¼ 0.650), also not when the analysis was restricted to patients older than 65 years (Table 2) .
Bevacizumab treatment
In the IDH wt cohort of 2010-2014, 117 of 241 patients (48.5%) received bevacizumab at any time during the disease course, compared with 32 of 166 patients (19.3%) in 2005-2009. Thirteen of 117 patients received bevacizumab as part of first-line treatment, mostly because these patients were included in the ARTE trial [8] . Next, we focused on patients who received bevacizumab at time of first recurrence and excluded all patients who had bevacizumab as part of first-line treatment, or who had no first-line treatment at all, or who had no salvage therapy. Based on these criteria, there were 59 patients who received bevacizumab and 62 patients who received any other bevacizumab-free treatment. No better PFS-2 (P ¼ 0.733) was seen for patients who received bevacizumab at first recurrence than for those who did not ( Figure 1A and B). Further, patients who did not receive bevacizumab at time of first recurrence had better PRS (10.8 months compared to 18.7 months, P ¼ 0.012; Figure 1C) , particularly in the subgroup of younger patients ( Figure 1D ). Yet, although age (P ¼ 0.060) and gender (P ¼ 0.563) were balanced between both groups, patients who received bevacizumab had more often a lower KPS (P < 0.001) and tumors with an unmethylated MGMT promoter than the control group (P ¼ 0.002; Table 3 ). Also, of patients who did not receive bevacizumab at time of first recurrence, 40 patients (65.6%) had bevacizumab later on. Among patients who did not have bevacizumab at time of first recurrence, those who received bevacizumab later on had comparable PRS as those who had not (P ¼ 0.678; Figure 1E ), and better PRS than patients who received bevacizumab at time of first recurrence (P ¼ 0.014; Figure 1E ). Twenty-one of 61 patients (34.4%), who had nonbevacizumab-based treatment at first recurrence, and 30 of 55 patients (54.5%), who had bevacizumab at time of first recurrence, had corticosteroids when salvage treatment was started (P ¼ 0.029; Table 3 ). Corticosteroid doses were cut by more than half in response to salvage therapy in 10 of 21 patients (47.6%) with non-bevacizumab regimens as opposed to 25 of 30 patients (83.3%) who had bevacizumab (P ¼ 0.007; Table 3 ).
Discussion
The VEGF antibody, bevacizumab (Avastin V R ), received approval for the treatment of recurrent glioblastoma in the USA, Switzerland and various other countries in 2009 or shortly thereafter, although not in the European Union. Since then, major trials in recurrent [5] and newly diagnosed glioblastoma [8] [9] [10] [11] consistently demonstrated prolonged PFS with bevacizumabcontaining regimens, but no effect on OS. It has remained unclear to what extent cross-over to bevacizumab in the control groups of these trials at progression contributed to the disconnect between PFS and OS. Further, the patients thought to benefit most from bevacizumab may be underrepresented in clinical trials.
Another approach to explore the potential value of bevacizumab in glioblastoma is to identify changes in OS on a population level. Here, we investigated patterns of care and outcome in glioblastoma patients living in the Canton of Zurich, Switzerland, from 2010 to 2014, using 2005-2009 data as a reference [7] . We report that the median OS did not significantly change from the pre-bevacizumab (2005) (2006) (2007) (2008) (2009) ) to the bevacizumab era (2010-2014) although the increase from 11.3 to 13.5 months in IDH wt patients indicates a further trend to improved outcome (Table 3 ; supplementary Figure S1 , available at Annals of Oncology online). Yet, detailed subgroup analyses failed to support the hypothesis that this apparent increase in OS is linked to the introduction of bevacizumab.
Major differences between our 2010-2014 and 2005-2009 cohorts include a higher number of patients diagnosed with glioblastoma at older age and a higher rate of biopsies (supplementary Table S1 , available at Annals of Oncology online). These observations might indicate that the practice of not verifying the diagnosis histologically and opting for best supportive care alone when the diagnosis is suspected on neuroimaging alonepatients who were not included in either cohort discussed in this article-has been abandoned. KPS at time of diagnosis was still balanced in both cohorts, possibly indicating earlier diagnosis, which could artificially improve survival data, too. While TMZ/ RT was most often used as first-line therapy in both patient cohorts, the use of bevacizumab at time of first recurrence significantly increased after its approval in 2009 (supplementary Table  S1 , available at Annals of Oncology online); yet, there was no apparent association of bevacizumab use and survival. Multivariate analysis confirmed young age, high-performance status, gross total resection and a methylated MGMT promoter in the tumor tissue, as well as first-line therapy based on combined chemoradiotherapy with TMZ, but not bevacizumab use, to be independently associated with survival (Table 2 ). In fact, on a population level, bevacizumab at time of first recurrence may not even be superior to any other bevacizumab-free regimen for PRS ( Figure  1C) , especially in young patients ( Figure 1D ). The lack of an association of bevacizumab use with PFS-2 may reflect negative patient selection for bevacizumab use at first recurrence (Table 3) or that not all observations from clinical trials, defined by selected patient cohorts, can be reproduced on a population level. Bevacizumab use at time of further recurrences was associated with better survival, although there was a selection bias since these patients usually had good performance status and tumors with methylated MGMT promotor. Yet, corticosteroid doses were much more often cut by more than half in patients who received bevacizumab at first recurrence than in those who did not (Table 3) . Although confirmation from a prospective study is pending, it is generally assumed that significantly lowering steroid doses translates into improved quality of life. Main limitations of this study include its retrospective nature and the small sample size at least for subgroups.
A first epidemiological study based on data from the Surveillance, Epidemiology, and End Results Program (SEER) in the United States reported improved median survival from 7 months for patients who died in 2008 to 9 months for patients who died in 2010 [12] . Although data on treatment were not available, the authors proposed bevacizumab use as the most likely explanation for this increase. A second SEER-Medicare analysis focusing on elderly patients [13] arrived at a similar conclusion, but we remain skeptical that very specific questions such as the impact of a new drug on survival can be adequately addressed using SEER data, given the absence of data on-and thus control formajor prognostic factors in glioblastoma, such as KPS, MGMT promoter methylation or IDH mutation, and the lack of an analysis of patterns of care at recurrence. Accordingly, we saw no such correlation of outcome with bevacizumab use when restricting the analysis to patients older than 65 years either ( Table 2) .
In summary, this study indicates that despite a strong increase in bevacizumab use in the Canton of Zurich, Switzerland, on a population level, the OS of patients with newly diagnosed glioblastoma has not significantly improved from the 2005 to 2009 period compared with 2010 to 2014. Future studies should seek to explore reduction of steroid dependence as a surrogate parameter of better quality of life. 
